Corient Private Wealth
CHRS icon

Corient Private Wealth’s Coherus Oncology CHRS Stock Holding History

Corient Private Wealth’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Sell
100,000
-2
-0% -$3 ﹤0.01% 2878
2026
Q1 		$169K Buy
100,002
+10,002
+11% +$17.8K ﹤0.01% 2600
2025
Q4 		$128K Hold
90,000
– – ﹤0.01% 2509
2025
Q3 		$148K Buy
90,000
+30,000
+50% +$33.4K ﹤0.01% 2398
2025
Q2 		$43.9K Buy
60,000
+10,000
+20% +$8.63K ﹤0.01% 2393
2025
Q1 		$40.4K Hold
50,000
– – ﹤0.01% 2236
2024
Q4 		$69K Hold
50,000
– – ﹤0.01% 2256
2024
Q3 		$52K Buy
50,000
+20,000
+67% +$27.4K ﹤0.01% 2393
2024
Q2 		$51.9K Buy
+30,000
New +$60.4K ﹤0.01% 2256

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Corient Private Wealth's CHRS Position: Q2 2026 in Review

Corient Private Wealth reduced its Coherus Oncology (CHRS) stake by 0% in Q2 2026, selling an estimated $3 and leaving 100,000 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Corient Private Wealth first reported a position in CHRS in Q2 2024 and has held it in 9 quarters since. The position peaked at $169K in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Corient Private Wealth held 100,000 shares of Coherus Oncology worth $140K as of Q2 2026.
  • Corient Private Wealth sold 2 Coherus Oncology shares in Q2 2026, an estimated $3.
  • Coherus Oncology made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2878 holding.
  • Corient Private Wealth first reported a position in Coherus Oncology in Q2 2024 and has held it in 9 quarters since.
  • Corient Private Wealth's Coherus Oncology position peaked at $169K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.